Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efsubaglutide Alfa in Overweight or Obesity
NCT07114419Phase 2Recruiting
- Sponsor
- Shanghai Innogen Pharmaceutical Technology Co., Ltd.
- Start
- Aug 2025
- Primary completion
- Jun 2026
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of efsubaglutide alfa in obesity, sponsored by Shanghai Innogen Pharmaceutical Technology Co., Ltd.. Started Aug 2025; status: recruiting.
02
Drugs
efsubaglutide alfa
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07114419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07114419.